Search results for "MHC"

showing 10 items of 233 documents

Optimized Protocol for the Detection of Multifunctional Epitope-Specific CD4+ T Cells Combining MHC-II Tetramer and Intracellular Cytokine Staining T…

2019

Analysis of multifunctional CD4+ T cells is fundamental for characterizing the immune responses to vaccination or infection. Major histocompatibility complex (MHC)/peptide tetramers represent a powerful technology for the detection of antigen-specific T cells by specific binding to their T-cell receptor, and their combination with functional assays is fundamental for characterizing the antigen-specific immune response. Here we optimized a protocol for the detection of multiple intracellular cytokines within epitope-specific CD4+ T cells identified by the MHC class II tetramer technology. The optimal procedure for assessing the functional activity of tetramer-binding CD4+ T cells was based o…

CD4-Positive T-Lymphocyteslcsh:Immunologic diseases. Allergymedicine.medical_treatmentImmunologyEpitopes T-LymphocyteMajor histocompatibility complexEpitopeimmune responseMice03 medical and health sciences0302 clinical medicineImmune systemMHC-II tetramersTetramerMethodsmedicineAnimalsImmunology and Allergy030304 developmental biology0303 health sciencesMHC class IIMHC-II tetramers ICS cytokines multifunctional T cells flow cytometry immune response vaccinationStaining and LabelingbiologyChemistryflow cytometryHistocompatibility Antigens Class IIvaccinationmultifunctional T cellscytokines3. Good healthCell biologyCytokineICSbiology.proteinFemaleAntibodyPeptideslcsh:RC581-607Intracellular030215 immunologyFrontiers in Immunology
researchProduct

Differential expression of alternative H2-M isoforms in B cells, dendritic cells and macrophages by proinflammatory cytokines.

1999

Major histocompatibility (MHC) class II heterodimers bind peptides generated by degradation of endocytosed antigens and display them on the surface of antigen presenting cells (APCs) for recognition by CD4+ T cells. Efficient loading of MHC class II molecules with peptides is catalyzed by the MHC class II-like molecule H2-M. The coordinate regulation of MHC class II and H2-M expression is a prerequisite for efficient MHC class II/peptide assembly in APCs determining both the generation of the T cell repertoire in the thymus and cellular immune responses in the periphery. Here we show that expression of H2-M and MHC class II genes is coordinately and cell type-specific regulated in splenic B…

CD74ImmunologyAntigen presentationGenes MHC Class IICD1Antigen-Presenting CellsGene ExpressionIn Vitro TechniquesMHC Class II GeneMiceMHC class IAnimalsProtein IsoformsMolecular BiologyDNA PrimersMHC class IIB-LymphocytesHLA-D AntigensMice Inbred BALB CbiologyBase SequenceAntigen processingHistocompatibility Antigens Class IIDendritic CellsMHC restrictionMolecular biologybiology.proteinMacrophages PeritonealCytokinesInflammation MediatorsMolecular immunology
researchProduct

H2-M, a facilitator of MHC class II peptide loading, and its negative modulator H2-O are differentially expressed in response to proinflammatory cyto…

2000

H2-M is a major histocompatibility complex (MHC) class II-like molecule that catalyzes peptide binding to MHC class II molecules. Recently, the H2-O heterodimer, encoded by H2-Oa and H2-Ob in the MHC class II region, has been shown to be physically associated with H2-M in B cells and to downregulate H2-M function. Examination of H2-O expression in freshly isolated mouse organs revealed that H2-Oa- and H2-Ob-specific transcripts are present in both lymphoid and nonlymphoid tissues. To evaluate the gene regulation and functional impact of H2-O on antigen presentation, we examined the effects on MHCII, invariant chain (Ii), H2-M, and H2-O gene expression of interleukin (IL)-4, IL-10, and inter…

CD74ImmunologyAntigen presentationchemical and pharmacologic phenomenaMajor histocompatibility complexInterferon-gammaMiceMHC class IGeneticsCIITAAnimalsTissue DistributionRNA MessengerAntigen PresentationHLA-D AntigensMHC class IIbiologyAntigen processingHistocompatibility Antigens Class IINuclear ProteinsMHC restrictionMolecular biologyInterleukin-10Antigens Differentiation B-LymphocyteGene Expression RegulationMice Inbred DBATrans-Activatorsbiology.proteinInterleukin-4PeptidesImmunogenetics
researchProduct

Multiple levels of MHC class I down-regulation by ras oncogenes.

1996

A number of tumours and oncogene transformed cells displayed reduced MHC class I surface expression which seemed to enable their escape from immune surveillance. To test whether oncogenic activation is directly involved in suppressing MHC class I expression, a model of inducible oncogene expression was chosen. Mouse fibroblasts transfected with different oncogenes expressed under the control of the dexamethasone-inducible MMTV promoter were analysed in the presence and absence of hormone for the mRNA and protein expression of MHC class I molecules as well as the respective oncogenes. Immunofluorescence analyses demonstrated an inverse association of MHC class I and oncogene expression after…

CD74Transcription GeneticImmunologyCD1Down-RegulationGene ExpressionC-C chemokine receptor type 7TransfectionDexamethasoneMiceAntigenMHC class IAnimalsRNA Processing Post-TranscriptionalPromoter Regions GeneticMessenger RNAbiologyOncogeneHistocompatibility Antigens Class IGeneral Medicine3T3 CellsMHC restrictionMolecular biologyGenes rasMammary Tumor Virus MouseAntigens Surfacebiology.proteinImmunoglobulin Heavy Chainsbeta 2-MicroglobulinScandinavian journal of immunology
researchProduct

Efficient Targeting of Protein Antigen to the Dendritic Cell Receptor DEC-205 in the Steady State Leads to Antigen Presentation on Major Histocompati…

2002

To identify endocytic receptors that allow dendritic cells (DCs) to capture and present antigens on major histocompatibility complex (MHC) class I products in vivo, we evaluated DEC-205, which is abundant on DCs in lymphoid tissues. Ovalbumin (OVA) protein, when chemically coupled to monoclonal alphaDEC-205 antibody, was presented by CD11c+ lymph node DCs, but not by CD11c- cells, to OVA-specific, CD4+ and CD8+ T cells. Receptor-mediated presentation was at least 400 times more efficient than unconjugated OVA and, for MHC class I, the DCs had to express transporter of antigenic peptides (TAP) transporters. When alphaDEC-205:OVA was injected subcutaneously, OVA protein was identified over a …

CD8-Positive T-LymphocytesMice0302 clinical medicineImmunology and AllergyCytotoxic T cellMice KnockoutAntigen Presentation0303 health sciencesMembrane GlycoproteinstoleranceAntibodies MonoclonalDEC-205 receptorrespiratory systemFlow CytometryEndocytosismedicine.anatomical_structureMHC class IFemaleOvalbuminT cellImmunologyAntigen presentationReceptors Cell Surfacechemical and pharmacologic phenomenaBiologyMajor histocompatibility complexArticleMinor Histocompatibility Antigens03 medical and health sciencesAntigenAntigens CDMHC class IImmune TolerancemedicineAnimalsLectins C-Typedendritic cellsAntigensCD40 Antigens030304 developmental biologyHistocompatibility Antigens Class IDendritic cellMolecular biologyCD11c AntigenMice Inbred C57BLCD8 T cellbiology.proteinLymph NodesCarrier ProteinsCD8030215 immunologyJournal of Experimental Medicine
researchProduct

Isolation of Differentially Expressed Genes in Epidermal Langerhans Cells

1997

Epidermal Langerhans cells (LC) represent immature dendritic cells (DC) resident in the skin, which are not yet able to prime naive T cells1. In vitro cultivation of LC in the presence of keratinocytes, supplying survival and differentiation signals, induces maturation events in LC2. These are highlighted by the downregulation of the biosynthesis of MHC class II molecules3, by the upregulation of the surface expression of adhesion and costimulatory molecules like CD80, CD86, CD54 and CD584,5, and by the acquisition of a potent immunostimulatory capacity for T cells6. Mature LC are potent inducers of naive T cells. Thus LC represent an ideal model system to investigate the maturation of DC (…

CD86Differential displaychemistry.chemical_compoundMHC class IIBiosynthesischemistryDownregulation and upregulationbiology.proteinInducerBiologyCD80In vitroCell biology
researchProduct

T-Cell Epitope Processing (The Epitope Flanking Regions Matter)

2009

Epitopes presented by major histocompatibility complex (MHC) class I molecules for cytotoxic T-lymphocyte (CTL) recognition are derived mainly from cytosolic proteins. Antigen presentation on the cell surface requires correct processing of epitopes by the proteasome, cytosolic and endoplasmic reticulum (ER) aminopeptidases, efficient TAP transport, and sufficient binding to MHC class I molecules. The efficiency of the epitope generation depends not only on the epitope itself but also on its flanking regions. To investigate preferences at the C-terminal epitope extension on processing and presentation, the SIINFEKL (S8L) epitope can be used as a model epitope. By exchanging the amino acids a…

CTL*biologyLinear epitopeChemistryEndoplasmic reticulumAntigen presentationMHC class Ibiology.proteinCytotoxic T cellMajor histocompatibility complexEpitopeCell biology
researchProduct

Deficient expression of components of the MHC class I antigen processing machinery in human cervical carcinoma.

2001

In cervical carcinomas abnormalities in the MHC class I surface expression are a frequent event, which are often associated with the deficient expression of the peptide transporter subunit TAP1 thereby resulting in impaired T cell response. In order to understand the role of other components of the MHC class I antigen processing machinery (APM) in the immune escape, 16 surgically removed primary cervical carcinoma lesions were analyzed for their mRNA expression of the heterodimeric peptide transporter TAP, the constitutive and interferon (IFN)-gamma inducible proteasome subunits and their activators PA28alpha/beta, various chaperones as well as MHC class I antigens. High expression levels o…

Cancer ResearchAntigen presentationBlotting WesternDown-RegulationGene ExpressionGenes MHC Class IUterine Cervical NeoplasmsHuman leukocyte antigenBiologyInterferon-gammaInterferonMHC class ImedicineBiomarkers TumorTumor Cells CulturedHumansRNA MessengerCells CulturedDNA PrimersAntigen PresentationAntigen processingMHC class I antigenReverse Transcriptase Polymerase Chain ReactionHistocompatibility Antigens Class ITransporter associated with antigen processingNeoplasm ProteinsPhenotypeOncologyImmunologyCancer researchbiology.proteinFemaleTAP1medicine.drugInternational journal of oncology
researchProduct

Presence on a human melanoma of multiple antigens recognized by autologous CTL.

1989

We derived from blood lymphocytes of a melanoma patient a large number of cytolytic T-cell clones directed against a cell line of the autologous tumor. Three distinct groups of antigens were recognized by these CTL on the autologous melanoma cells: group A consisted of stable antigens present on all sublines, whereas antigens B and C appeared unstable and were expressed by distinct sublines. In vitro immunoselections with various anti-A CTL clones were applied to the melanoma cells and variants resistant to 3 different CTL clones were obtained. These variants remained sensitive to other anti-A CTL clones, indicating that group A comprises at least 4 different antigens (D, E, F and A'). From…

Cancer ResearchCellular immunitySkin NeoplasmsLymphocyteGenes MHC Class IHuman leukocyte antigenBiologyCell LineAntigenAntigens NeoplasmHLA AntigensmedicineTumor Cells CulturedHumansPan-T antigensMelanomaMelanomaGenetic Variationmedicine.diseaseClone CellsGene Expression Regulation NeoplasticCytolysisCTL*medicine.anatomical_structureOncologyImmunologyLymphocyte Culture Test MixedT-Lymphocytes CytotoxicInternational journal of cancer
researchProduct

Abstract A110: Mutant MHC class II epitopes drive therapeutic immune responses to cancer

2016

Abstract Mutations are regarded as ideal targets for cancer immunotherapy. As neoepitopes with strict lack of expression in any healthy tissue, they are expected to be safe and could bypass the central tolerance mechanisms. Recent advances in nucleic acid sequencing technologies have revolutionized the field of genomics, allowing the readily targeting of mutated neoantigens for personalized cancer vaccination. We demonstrated in three independent murine tumor models that a considerable fraction of non-synonymous cancer mutations is immunogenic and that unexpectedly the immunogenic mutanome is pre-dominantly recognized by CD4+ T cells. RNA vaccination with such MHC class II restricted immuno…

Cancer ResearchMHC class IIbiologymedicine.medical_treatmentT cellImmunologyVirologyEpitopemedicine.anatomical_structureAntigenCancer immunotherapybiology.proteinmedicineCancer vaccineCentral toleranceCD8Cancer Immunology Research
researchProduct